Jul 14, 2024
Enamine Germany Joins the MC4DD Consortium
We at Enamine Germany are thrilled to announce our participation in the prestigious Macrocycles for Drug Discovery (MC4DD) consortium, coordinated by the TU Darmstadt. This cutting-edge initiative is set to revolutionize the field of drug discovery through the collaborative efforts of leading universities and pharmaceutical companies across Europe and associated countries.
Unleashing the Potential of Macrocycles
Macrocycles represent a unique class of drug-like molecules characterized by their large ring structures, comprising more than 12 atoms. These compounds are known for their complex architecture and exceptional properties, offering potential solutions where traditional pharmacological approaches may falter. Despite their promising attributes, the synthesis and application of macrocycles have encountered significant technical challenges, limiting their broader clinical application—challenges that the MC4DD consortium is dedicated to overcoming.
A Multinational Effort
Supported by the Marie Skłodowska-Curie Actions (MSCA) program of the European Union, the MC4DD consortium harnesses the expertise and resources of participants from Germany, Sweden, Ukraine, Italy, the Netherlands, Switzerland, and the UK. Our collaborative goal is to enhance the synthetic accessibility, computational predictability, and pharmacological understanding of macrocycles, focusing on challenging drug targets associated with cancer, depression, obesity, and chronic pain.
Commitment to Innovation and Education
Under the leadership of Professor Felix Hausch of TU Darmstadt, MC4DD is not only a hub for advanced research but also a center for educational excellence. The consortium will train 17 highly skilled PhD students, equipping the next generation of scientists with the knowledge and tools necessary to lead future innovations in drug discovery.
For further details on this exciting collaboration, please read our full press release here.